GeneTherapyLive’s Weekly Rewind – September 17, 2021


Review top news and interview highlights from the week ending September 17, 2021.

Welcome to GeneTherapyLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Addressing Exhausted T-Cells in CAR T Therapy: Joseph A. Fraietta, PhD

The director of the Solid Tumor Immunotherapy Lab at the University of Pennsylvania discussed the issue of exhausted T-cells, touching on the role of BET proteins in T-cell function and their mechanism of exhaustion.

2. Astellas Pauses Gene Therapy Trial for X-Linked Myotubular Myopathy

Following Astellas Pharma’s voluntary pause of their ASPIRO trial due to a patient experiencing a serious liver AE, the trial has now been placed on a second clinical hold after the patient died. This marks the fourth death over the course of the trial.

3. Elucidating the Role of HTRA1 in Developing AMD: Gregory S. Hageman, PhD; Brandi L. Williams, PhD

Directors from the Moran Eye Center discussed their research on the genetics of age-related macular degeneration, including the mechanism of AMD and their discovery of the protective effect of the HTRA1 gene.

4. T Cell Therapy Trial for High-Risk Patients With COVID-19 Now Enrolling

Tevogen Bio and Thomas Jefferson University are beginning enrollment of their phase 1 trial of TVGN-489 for the treatment of high-risk patients with COVID-19, which could potentially be the first cell therapy treatment for the virus.

5. TAC T-Cell Therapy vs CAR T-Cell Therapy

Paul Lammers, MD, MSc, the president and chief executive officer of Triumvira Immunologics, discussed the company’s T-cell antigen coupler technology, its potential in both hematologic malignancies and solid tumors, and their investigations in their lead program, TAC-01 HER2.

Related Videos
Leigh Ramos-Platt, MD, on Sharing Experience With Gene Therapy Administration
Daniel Hart, PhD, on CRISPR-Mediated, In Vivo Epigenomic Activation
Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure
PJ Brooks, PhD, on Improved Newborn Screening, Non-Viral Gene Editing: New Frontiers for Neuromuscular Disease
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
© 2024 MJH Life Sciences

All rights reserved.